Puromycin Aminonucleoside: Gold-Standard Nephrotoxic Agent for Podocyte Injury Models

Executive Summary: Puromycin aminonucleoside is a well-characterized nephrotoxic agent derived from puromycin’s aminonucleoside moiety (APExBIO). It reliably induces proteinuria and podocyte injury in rodent models, recapitulating key features of focal segmental glomerulosclerosis (FSGS) (Meng et al., 2017). Mechanistically, it disrupts podocyte architecture and reduces nephrin expression, critical for glomerular filtration. Uptake is enhanced in PMAT-expressing cells at acidic pH, supporting mechanistic dissection of transporter-mediated nephrotoxicity. High solubility and robust stability protocols make it a preferred tool for precision renal injury modeling.

Biological Rationale

Puromycin aminonucleoside (CAS 58-60-6) is the aminonucleoside fragment of the antibiotic puromycin. It is used extensively in nephrology research for its reproducible induction of nephrotic syndrome-like states in animal models, particularly rats and mice (APExBIO). Unlike the parent compound, puromycin aminonucleoside lacks significant antimicrobial activity but retains potent cytotoxicity toward renal podocytes. Podocyte injury is central to the pathogenesis of nephrotic syndrome and FSGS, making this compound invaluable for modeling glomerular diseases (Dimesna article). This article extends upon prior summaries by focusing on solubility parameters, PMAT transporter relevance, and recent cytotoxicity benchmarks.

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside selectively targets renal podocytes. In vitro, it causes loss of microvilli and effacement of foot processes in cultured podocytes, leading to disruption of the filtration barrier (Bridgene article). Uptake into cells is augmented by the plasma membrane monoamine transporter (PMAT), especially at acidic pH (6.6). This property allows for model systems dissecting transporter-mediated nephrotoxicity. The compound reduces nephrin expression in podocytes, a hallmark of glomerular filtration barrier dysfunction. Puromycin aminonucleoside is cytotoxic in vector-transfected and PMAT-transfected MDCK cells, with half-maximal inhibitory concentration (IC50) values of 48.9 ± 2.8 μM and 122.1 ± 14.5 μM, respectively, under defined conditions (DMSO vehicle, 37°C, 24 h exposure).

Evidence & Benchmarks

• Intravenous administration in rats induces proteinuria and glomerular lesions that closely resemble human FSGS (Meng et al., 2017).
• Pretreatment of podocyte cultures with puromycin aminonucleoside leads to loss of microvilli and foot-process effacement observed by electron microscopy (Yeast Extract article).
• In PMAT-expressing MDCK cells, the compound’s cytotoxicity is increased at pH 6.6, supporting transporter-mediated uptake mechanisms (APExBIO product documentation).
• Solubility is ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water with gentle warming (manufacturer’s data sheet: APExBIO).
• Short-term solution stability is optimal at -20°C, and stability declines if stored at higher temperatures or for extended periods (APExBIO).
• Experimental use in rats reliably reduces nephrin expression and triggers lipid accumulation in mesangial cells (Bridgene article).

Applications, Limits & Misconceptions

Puromycin aminonucleoside is the gold-standard nephrotoxic agent for inducing proteinuria and glomerular lesions in experimental nephrology (Egg White Lysozyme article). This article clarifies recent advances in workflow integration and cytotoxicity measurement, whereas prior articles focused mainly on mechanistic or historical aspects.

• Used for modeling nephrotic syndrome, FSGS, and glomerular injury in vivo and in vitro.
• Supports evaluation of candidate therapeutics that target podocyte preservation or function.
• Enables reductionist studies on the impact of transporter expression (PMAT) on compound uptake and toxicity.
• Facilitates biomarker discovery for nephrotic injury, such as nephrin downregulation.
• Not suitable for modeling immunologically mediated renal diseases or conditions where podocyte-independent mechanisms predominate.

Common Pitfalls or Misconceptions

• Not an immunological model: Puromycin aminonucleoside does not induce immune-complex glomerulonephritis; results are specific to direct podocyte injury.
• Species specificity: Rodent models respond robustly; other species may not recapitulate human FSGS features.
• Solution stability: Solutions are prone to degradation above -20°C or when stored for more than a few days.
• Reversal limitations: Once podocyte damage is induced, spontaneous recovery is limited without intervention.
• Non-antimicrobial: Unlike puromycin, the aminonucleoside moiety lacks significant antibacterial activity.

Workflow Integration & Parameters

Puromycin aminonucleoside is supplied as a crystalline solid and is highly soluble in DMSO, ethanol, and water. For in vivo studies, the recommended administration routes are intravenous or subcutaneous injection in rats, using doses calibrated to induce nephrotic-range proteinuria over 3–10 days. For in vitro podocyte injury models, working concentrations typically range from 10–100 μM, with defined exposure times (usually 24–48 h). Solutions should be freshly prepared or stored at -20°C and used within 1–2 days to ensure integrity (APExBIO).

APExBIO (A3740) provides validated product specifications and batch-tested purity for reproducible results. For advanced applications, the compound’s PMAT-dependent uptake at acidic pH can be used to dissect transporter contributions to nephrotoxicity (Egg White Lysozyme). This article updates prior workflow guides by providing cytotoxicity benchmarks, solubility data, and explicit recommendations for solution handling and storage.

Conclusion & Outlook

Puromycin aminonucleoside remains the reference nephrotoxic agent for modeling podocyte injury and proteinuria. Its robust, reproducible effects in rodent models underpin translational research into nephrotic syndrome and FSGS. Current advances leverage PMAT-mediated uptake and precision cytotoxicity benchmarks to enable more mechanistic renal research. Continued innovation in podocyte and transporter biology will refine the utility of this compound in preclinical nephrology. For authoritative sourcing and product specifications, refer to the APExBIO product page.